e-learning
resources
ERJ
2016
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Unfavourable effects of medically indicated oral anticoagulants on survival in idiopathic pulmonary fibrosis: methodological concerns
Leticia Kawano-Dourado, Fernando Zampieri, Alexandre Biasi Cavalcanti, Lucas Petri Damiani and Ronaldo Adib Kairalla; Michael Kreuter, Marlies S. Wijsenbeek, Martina Vasakova, Paolo Spagnolo, Martin Kolb, Ulrich Costabel, Derek Weycker, Klaus-Uwe Kirchgaessler and Toby M. Maher
Source:
Eur Respir J 2016; 48: 1523-1524
Journal Issue:
November
Disease area:
Interstitial lung diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Leticia Kawano-Dourado, Fernando Zampieri, Alexandre Biasi Cavalcanti, Lucas Petri Damiani and Ronaldo Adib Kairalla; Michael Kreuter, Marlies S. Wijsenbeek, Martina Vasakova, Paolo Spagnolo, Martin Kolb, Ulrich Costabel, Derek Weycker, Klaus-Uwe Kirchgaessler and Toby M. Maher. Unfavourable effects of medically indicated oral anticoagulants on survival in idiopathic pulmonary fibrosis: methodological concerns. Eur Respir J 2016; 48: 1523-1524
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Serum KL-6 as a biomarker for interstitial lung diseases in a clinical setting: application of a fully automated immunoassay.
The cryoTBB role in the diagnostic work-up of IPF: an European perspective; emergent standardization guidelines
Acute exacerbations of IPF: A neglected threat in IPF ?
Related content which might interest you:
Unfavourable effects of medically indicated oral anticoagulants on survival in idiopathic pulmonary fibrosis
Source: Eur Respir J 2016; 47:1776-1784
Year: 2016
Long-term outcomes of antifibrotic treatments in patients with idiopathic pulmonary fibrosis: Real-world experience
Source: Virtual Congress 2020 – Real life in the field of idiopathic pulmonary fibrosis: treatments and registries
Year: 2020
Real-world antifibrotic treatment persistence and clinical outcomes for patients with idiopathic pulmonary fibrosis
Source: Virtual Congress 2021 – Interstitial lung disease around the world
Year: 2021
Concomitant medications and clinical outcomes in idiopathic pulmonary fibrosis
Source: Eur Respir J, 54 (6) 1901188; 10.1183/13993003.01188-2019
Year: 2019
The effect of anti-acid therapy on survival in idiopathic pulmonary fibrosis: a methodological review of observational studies
Source: Eur Respir J, 51 (6) 1800376; 10.1183/13993003.00376-2018
Year: 2018
ERJ June Podcast: unfavourable effects of oral anticoagulants on survival in idiopathic pulmonary fibrosis
Source: Eur Respir J 2016; 47:E66
Year: 2016
Effect of metformin on clinically relevant outcomes in patients with idiopathic pulmonary fibrosis (IPF)
Source: International Congress 2017 – ILDs: clinical aspects
Year: 2017
Pirfenidone safety and adverse event management in idiopathic pulmonary fibrosis
Source: Eur Respir Rev, 26 (146) 170057; 10.1183/16000617.0057-2017
Year: 2017
LATE-BREAKING ABSTRACT: Detrimental effects of medically indicated oral anticoagulation on survival in idiopathic pulmonary fibrosis (IPF)
Source: International Congress 2015 – Latest developments in clinical studies in acute and chronic lung diseases
Year: 2015
Mortality outcomes in patients with idiopathic pulmonary fibrosis treated with antifibrotics: a real world study
Source: Virtual Congress 2021 – News in treatment and diagnosis of idiopathic interstitial pneumonia
Year: 2021
Predictors of effects and adverse effects of pirfenidone on idiopathic pulmonary fibrosis
Source: Annual Congress 2012 - Idiopathic pulmonary fibrosis
Year: 2012
Emerging potential treatments: new hope for idiopathic pulmonary fibrosis patients?
Source: Eur Respir Rev 2011; 20: 201-207
Year: 2011
Factors affecting the compliance to antifibrotic treatment in patients with interstitial pulmonary fibrosis
Source: International Congress 2019 – The world of idiopathic pulmonary fibrosis
Year: 2019
Patients’ expectations and quality of life before introduction of pirfenidone used in idiopathic pulmonary fibrosis.
Source: International Congress 2018 – Management of idiopathic interstitial pneumonias: established and new treatments
Year: 2018
Long-term clinical and real-world experience with pirfenidone in the treatment of idiopathic pulmonary fibrosis
Source: Eur Respir Rev 2015; 24: 58-64
Year: 2015
Efficacy of switching antifibrotic therapy in idiopathic pulmonary fibrosis: real life data
Source: International Congress 2019 – The world of idiopathic pulmonary fibrosis
Year: 2019
The INPULSIS trials of idiopathic pulmonary fibrosis treatment: explaining further discrepancies on exacerbations
Source: Eur Respir J 2016; 47: 344-345
Year: 2016
Comorbidities influence in idiopathic pulmonary fibrosis antifibrotic treatments
Source: International Congress 2019 – Comorbidities of idiopathic pulmonary fibrosis
Year: 2019
Discrepancy between patient expectations and experiences with anti-fibrotic drugs in idiopathic pulmonary fibrosis
Source: International Congress 2017 – Idiopathic pulmonary fibrosis: from the bench to the bedside
Year: 2017
Does delay in review of newly-diagnosed idiopathic pulmonary fibrosis (IPF) worsen outcomes?
Source: International Congress 2018 – News on the diagnosis of idiopathic interstitial pneumonia
Year: 2018
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept